{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:25:26Z","timestamp":1787765126789,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Urothelial carcinomas of the bladder are more common in males, making them the sixth-most common cancer in men and the tenth-most common cancer overall, worldwide. Current guidelines do not recommend routine testing for human epidermal growth factor receptor (HER2\/neu) expression on the biopsy specimens of patients with urothelial carcinoma. This study was aimed at determining the expression pattern of HER2\/neu and its usefulness in muscle-invasive and nonmuscle-invasive urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>HER2\/neu expression was assessed in 89 specimens of urothelial cancer by immunohistochemistry (IHC), and equivocal cases were subjected to fluorescent in situ hybridization (FISH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>On IHC for HER2\/neu, 17.9% (7\/39) of the muscle-invasive bladder cancers (MIBCs) showed a 3+ expression, whereas 22% (11\/50) of the non-muscle invasive cancers were positive with a score of 3+. A significant correlation between HER2\/neu status and muscle invasion could not be established in the current study (P = 0.74, Fisher\u2019s exact test). Three cases of muscle-invasive (7.7%) and 2 cases (4%) among nonmuscle invasive cancers showed equivocal expression. All the cases with equivocal (2+) expression on IHC were subjected to FISH and none showed gene amplification on hybridization and were considered as negative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Overexpression of HER-2\/neu was seen in 17.9% of MIBCs and 22% of non-MIBCs. There are no norms for routine testing of HER2\/neu expression in the biopsy specimens of urothelial carcinoma. There is an unmet need to establish guidelines for HER2\/neu scoring, similar to that for breast and gastric cancers, to determine the proportion of positive cases and help in identification of those who may benefit from targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/iju.iju_287_23","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T07:00:29Z","timestamp":1703833229000},"page":"44-48","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Human epidermal growth factor receptor 2\/neu expression in urothelial carcinomas"],"prefix":"10.4103","volume":"40","author":[{"given":"Arsha Balakrishnan","family":"Soudamini","sequence":"first","affiliation":[{"name":"Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasma","family":"Nalwa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam Ram","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotsna Naresh","family":"Bharti","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam Abhay","family":"Elhence","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil Dhanesh","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"R1-20240903","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"R2-20240903","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JOP.19.00215","article-title":"Management of urothelial bladder cancer in clinical practice: Real-world answers to difficult questions","volume":"15","author":"Mar","year":"2019","journal-title":"J Oncol Pract"},{"key":"R3-20240903","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clgc.2020.11.006","article-title":"The evolving landscape of antibody-drug conjugates for urothelial carcinoma","volume":"19","author":"Abel","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 16","key":"R4-20240903","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2022.40.16_suppl.4520","article-title":"RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials","volume":"40","author":"Sheng","year":"2022","journal-title":"JCO"},{"key":"R5-20240903","first-page":"852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int 2014"},{"key":"R6-20240903","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R7-20240903","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/14737159.2015.992416","article-title":"HER2 assessment by silver in situ hybridization: Where are we now?","volume":"15","author":"Sanguedolce","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"R8-20240903","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/cells11050803","article-title":"Antibody-drug conjugates in urothelial carcinoma: A new therapeutic opportunity moves from bench to bedside","volume":"11","author":"Ungaro","year":"2022","journal-title":"Cells"},{"key":"R9-20240903","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/mc.2940030503","article-title":"Amplification and expression of the c-erb B-2\/neu proto-oncogene in human bladder cancer","volume":"3","author":"Zhau","year":"1990","journal-title":"Mol Carcinog"},{"key":"R10-20240903","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/2278-330X.173164","article-title":"Human epidermal growth factor receptor 2\/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype?","volume":"4","author":"Kumar","year":"2015","journal-title":"South Asian J Cancer"},{"key":"R11-20240903","first-page":"457","article-title":"Prognostic impact of HER2\/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years'research","volume":"14","author":"Skagias","year":"2009","journal-title":"J BUON"},{"key":"R12-20240903","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R13-20240903","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11255-007-9283-x","article-title":"Prognostic significance of Her2\/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy","volume":"40","author":"Kolla","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"R14-20240903","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/2090598X.2020.1814183","article-title":"Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy","volume":"18","author":"Agrawal","year":"2020","journal-title":"Arab J Urol"},{"key":"R15-20240903","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"}],"container-title":["Indian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/iju.iju_287_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:59:49Z","timestamp":1787763589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/iju.iju_287_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/iju.iju_287_23","relation":{},"ISSN":["0970-1591","1998-3824"],"issn-type":[{"value":"0970-1591","type":"print"},{"value":"1998-3824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]},"assertion":[{"value":"2023-07-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}